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Abstract
Soft tissue sarcomas of childhood are a group of
heterogeneous tumors thought to be derived from
mesenchymal stem cells. Surgical resection is effective
only in about 50% of cases and resistance to
conventional chemotherapy is often responsible for
treatment failure. Therefore, investigations on novel
therapeutic targets are of fundamental importance.
Deregulation of epigenetic mechanisms underlying
chromatin modifications during stem cell
differentiation has been suggested to contribute to
soft tissue sarcoma pathogenesis. One of the main
elements in this scenario is enhancer of zeste
homolog 2 (EZH2), a methyltransferase belonging to
the Polycomb group proteins. EZH2 catalyzes histone
H3 methylation on gene promoters, thus repressing
genes that induce stem cell differentiation to
maintain an embryonic stem cell signature. EZH2
deregulated expression/function in soft tissue
sarcomas has been recently reported. In this review,
an overview of the recently reported functions of
EZH2 in soft tissue sarcomas is given and the
hypothesis that its expression might be involved in
soft tissue sarcomagenesis is discussed. Finally, the
therapeutic potential of epigenetic therapies
modulating EZH2-mediated gene repression is
considered.
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Introduction
Soft tissue sarcomas: a clinical challenge
Soft tissue sarcomas (STSs) are a group of heteroge-
neous malignant neoplasms thought to arise from mole-
cular lesions occurring during the differentiation of
mesenchymal stem cells (MSCs) [1]. STSs account for
less than 1% of all adult tumors and for about 15% of
all pediatric ones, with an estimated 10,520 new cases in
the US in 2010 [2,3]. A series of chromosomal translo-
cations have been identified as hallmarks of most STSs,
such as t(X;18)(p11.2;q11.2) in synovial sarcoma, t
(11;22)(q24;q12) in Ewing’s sarcoma, t(2;13)(q35;q14)
and t(1;13)(p36;q14) in alveolar rhabdomyosarcoma
(RMS). These chromosomal rearrangements result in
oncogenic fusion proteins that play direct roles in alter-
ing gene expression pattern in STS, promoting tumor
aggressiveness. Because of their infiltrating behavior,
only 50% of STSs are suitable for radical surgical resec-
tion. Moreover, a fraction of STSs are resistant to che-
motherapeutic agents, especially the metastatic forms
[4]. Doxorubicin, the drug used in standard single-agent
chemotherapy protocols for the treatment of metastatic
STS, results in only 20% to 25% response rates. Even
the combination of doxorubicin with other agents, such
as ifosfamide, has not dramatically improved the overall
5-year survival rate, which is no higher than 50% to 60%
[4]. Nevertheless, chemotherapy represents the only
viable strategy for palliation of symptoms in patients
with metastatic disease, improving their quality of life
[5]. New promising biological drugs, such as monoclonal
antibodies to insulin-like growth factor receptor (IGFR),
inhibitors of multityrosine kinases, and mammalian tar-
get of rapamycin (mTOR), have been introduced in STS
clinical trials (Table 1) [4]. However, disease stabilization
is still not seen in many patients, especially those
affected by peculiar histological variants or showing
poor-risk factors; it is reasonable to hypothesize that a
combination of cytotoxic chemotherapy with targeted
agents may be more appropriate to improve outcome in
STS patients. A novel class of therapeutic targets is
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Biological molecular
agents
Molecular target(s) Clinical studies (phase) and clinical efficiency Reference
Tyrosine kinase inhibitors
(TKIs)
Imatinib mesylate (IM) c-Kit, PDGFR Phase II study: 53.7% of patients with GISTs showed a partial response,
27.9% of patients showed stable disease, 13.6% of patients showed early
resistance to imatinib, 5% of patients showed serious adverse events
[60]
Phase III study: confirmation of the effectiveness of imatinib as primary
systemic therapy for patients with incurable GIST. No advantages to
higher dose treatment were reported.
[61]
Sunitinib malate (SM) VEGF-R1, VEGF-R2, VEGF-R3, c-Kit,
PDGFR, Flt-3, CSF1, neurotrophic
factor receptors
Phase III study: 7% of patients with GIST showed partial response, 58%
had stable disease, 19% had progressive disease; 27.3 weeks was the
time-to-tumor progression for sunitinib vs 6.4 weeks for placebo.
Progression-free survival was similar.
[62]
Phase II study: 3-month progression-free rate of >40% for liposarcomas
leiomyosarcomas
[63]
Phase II study: 52% of patients showed metabolic stable disease, 20% of
patients achieved stable disease for at least 16 weeks, 47% of patients
achieved partial response
[64]
Phase II study (current): SM activity in patients with certain subtypes of
STS. The majority of these patients showed stable disease for 16 weeks.
[65]
Sorafenib VEGF-R2, VEGF-R3, c-Kit,
PDGFR, Raf/Mek/Erk
Phase II study: 14% of patients with angiosarcoma and 6% of patients
with leiomyosarcoma had a response, 64% of patients developed
intolerance at the drug dose used
[66]
Phase II study: 78% patients with vascular tumors showed disease
stabilization
[67]
Phase II study (current): antitumor activity and acceptable toxicity profile
in patients with antracycline-refractory STS
[68]
Pazopanib VEGF-Rs Phase II study: 12-week progression-free survival was reached by 44%
patients with leiomyosarcoma, 49% of patients with synovial sarcomas,
and 39% of patients with the other STS types
[69]
Nilotinib BCR/ABL, c-Kit, PDGFR,
CSF1R
Phase I study: nilotinib alone or in combination with imatinib was well
tolerated and showed clinical activity in imatinib-resistant GIST patients
[70]
Mammalian target of
rapamycin (mTOR)
inhibitors
Tensirolimus mTOR Phase II study: moderate toxicity and limited clinical activity [71]
Everolimus mTOR Phase II study: acceptable toxicity. Limited clinical activity in heavily
pretreated patients with bone and soft tissue sarcomas. The efficacy in
imatinib-refractory and sunitinib-refractory GIST is promising.
[72]
Ridaforolimus (AP23573) mTOR Phase I study: safety of the drug; 27% of patients showed stable disease. [73]
Phase II study: 29% of clinical benefit rate. Prolongation of survival. [74]
Phase III study (current) [75]
Insulin-like growth factor
(IGF) receptor antibodies
Figitumumab IGF-1R Phase I study: good tolerance of the drug [76]
R1507 IGF-1R Phase II study (current): R1507 is well tolerated. Significant activity has
been observed in Ewing’s sarcoma, RMS and OS with several dramatic
responses seen in Ewing’s sarcoma and RMS.
[77]
AMG479 IGF-1R Phase I study: absence of severe toxicities [78]
Mk-0646 IGF-1R Phase I study (current) [79]
CSF1 = colony stimulating factor 1; Flt = fms-related tyrosine kinase; GIST = gastrointestinal stromal tumor; OS = osteosarcoma; PDGFR = platelet-derived growth
factor receptor; RMS = rhabdomyosarcoma; VEGF = vascular endothelial growth factor.
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methyltransferases (DNMTs), histone acetylases (HATs),
histone deacetylases (HDACs), and histone methyltrans-
ferases (HMTs). Physiologically, all these enzymes work
in concert for regulating gene expression by modifying
the state of chromatin without altering DNA gene
sequences in order to obtain a proper tissue determina-
tion. Increasing evidence demonstrates that they play
key roles in human tumorigenesis, often being deregu-
lated in terms of expression and/or activity and leading
to silencing of essential regulators of cell proliferation
and differentiation. Indeed, from comparative analyses,
it appears that cancer genomes show different patterns
of epigenetic modifications as compared to normal cells.
Using inhibitory agents of all of these enzymes, it is pos-
sible to obtain pharmacological reversion of the tumor-
specific gene expression profile, as well as reactivation
of abnormally silenced tumor-suppressor genes in can-
cer cells [6]. Among these regulatory players, the histone
methyltransferase enhancer of zeste homolog 2 (EZH2)
is considered one of the most appealing epigenetic tar-
gets for therapy in human cancer [7].
The Polycomb group protein EZH2 in STS
EZH2 is one of the Polycomb group (PcG) proteins,
which repress expression of developmentally regulated
genes that induce tissue differentiation, such as homeotic
genes. PcG proteins help maintaining the undifferen-
tiated, multipotent phenotype of the embryonic stem cell
compartment [7-11]. In vertebrates, PcG proteins form
two different groups of multiprotein Polycomb repressor
complexes (PRCs), PRC1 and PRC2/3. EZH2 is the cata-
lytic unit of the PRC2/3 complex, the part involved in the
initiation of gene repression. EZH2 methylates lysine 27
of histone H3, thus generating the H3K27-trimethylated
epigenetic mark that is recognized by the PRC1 complex
for further, long-term chromatin modifications (Figure
1a) [8]. EZH2 is promptly downregulated during progeni-
tor cell differentiation, becoming undetectable in adult
specialized cells and tissues (Figure 1b) [12]. Conversely,
EZH2 is abnormally overexpressed in a wide range of
tumors as compared with corresponding normal tissues,
its level of expression being correlated with cancer
aggressiveness [7,13,14]. Moreover, the abundance of
EZH2 molecules induces the formation of more repressor
complexes and, by altering the balance between different
PcG components, may lead to the formation of tumor-
specific PRC complexes that show differential substrate
specificities [15]. As a result, not only the general level of
repression but also the specificity of repressed genes is
changed. EZH2 has recently been found aberrantly
expressed in aggressive and poorly differentiated breast
and prostate carcinomas [13,14], as well as in STS
[16,17]. EZH2 aberrant overexpression may be one of the
molecular lesions occurring in differentiating mesenchy-
mal stem cells (MSCs), which are thought to be the cells
of origin of STS [1]. It has been proposed that the pre-
sence of EZH2 in tumors with embryonal features and
stem-cell phenotype, such as STS, may explain their
undifferentiated and immature character. In view of
these data, EZH2 appears to be an attractive target for
investigation in STS.
EZH2 in RMS
RMSs are a heterogeneous group of STSs characterized
by features of skeletal muscle tissue and thought to be
caused by abnormalities occurring during the course of
myogenesis [18,19]. It prevalently affects pediatric
patients and accounts for almost 50% of all STSs [20].
Classically, RMSs are histologically subdivided in two
subtypes: the alveolar and embryonal forms. More
recently, it has been reported that a diagnosis of alveolar
RMS can be made only in the presence of two specific
molecular aberrations, namely t(2;13)(q35;q14) and/or t
(1;13)(p36;q14) chromosomal translocations resulting in
PAX3-FKHR and the rarer PAX7-FKHR oncogenic
fusion proteins, respectively [21]. These lesions have
been found in about 20% of all RMSs and in about 70%
of the RMSs with an alveolar histology [21,22]. True
alveolar RMSs are often metastatic at diagnosis, show
unresponsiveness to conventional therapy and have poor
prognosis, the long-term survival rate being < 25%
[23,24]. Fusion-negative RMSs include tumors with
embryonal histology and the remaining part of RMSs
with an alveolar histology [18]. Evidence for aberrant
overexpression of EZH2 in RMS samples has been
reported by Wang and colleagues [25] and by our studies
in RMS cell lines and primary samples [16]. We have
recently confirmed this finding in a large cohort of RMS
specimens, documenting that overexpression of EZH2 is
a hallmark of RMS, independently of the histological sub-
type [26]. It remains to be determined whether the level
of EZH2 expression correlates with the presence of
fusion proteins typical of the alveolar subtype. These
results are consistent with the observation that in a phy-
siological context EZH2 inhibits muscle differentiation of
normal myoblasts by silencing muscle-specific genes [27].
Among these genes are those encoding for promyogenic
microRNAs, such as miR-214 and miR-29. These belong
to a class of small RNAs that inhibits the translation of
selected mRNAs thus preventing their protein expression
[25,28]. Mir-26a is another microRNA acting to post-
transcriptionally repress EZH2 in normal myoblasts
undergoing differentiation (Figure 2a left panel) [29].
During differentiation, miR-29 is induced and targets the
PcG transcription factor yin yang 1 (YY1) mRNA pro-
moting its degradation (Figure 2a left panel). In the
absence of a myogenic stimulus and in RMS cells, EZH2
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scription of both myofibrillary genes [27,30] and miR-29
(Figure 2a right panel) [25]. Similarly, miR-214 is directly
repressed by EZH2 in undifferentiated committed myo-
blasts and, in turn, it is able to bring about negative feed-
back on EZH2 during myogenesis by targeting its
transcript [28]. A role for miR-26a and miR-29 in RMS
pathogenesis was confirmed by recent studies [16,25]. We
found that miR-26a is aberrantly downregulated in RMS
cell lines and primary tumors as compared to non-tumor
counterparts, and that miR-26a loss of expression is paral-
leled by an overexpression of EZH2 [16]. Similarly, miR-29
levels are reduced in tumor samples as compared with
control muscle tissues. This finding can be interpreted
considering that overexpressed EZH2 and YY1 are capable
to repress miR-29 transcription in RMS cells (Figure 2a)
Figure 1 Schematic representation of transcriptional gene repression by enhancer of zeste homolog 2 (EZH2). (A) In a mesenchymal
stem cell or in a soft tissue sarcoma (STS) cell, EZH2 interacts with suppressor of zeste 12 (SUZ12) and embryonic ectoderm development (EED),
the other core components of the Polycomb repressor complex 2 (PRC2) complex that is involved in the initiation of gene repression. By the
methyltransferase activity of EZH2, histone H3 is methylated on K27 thus generating the epigenetic mark H3K27Me
3 that serves as a signal for
the recruitment of PRC1 complex. PRC1 DNA binding prevents the access of antagonistic chromatin remodeling factors, such as the SWI/SNF
complex, thus stabilizing the repressive state of the chromatin. The PRC2-associated activity of histone deacetylase (HDAC) and the interaction of
EZH2 with DNA methyltransferases (DMNTs) allow a further compaction of chromatin by means of histone deacetylation and DNA methylation,
respectively (synergism of epigenetic mechanisms). (B) During differentiation the level of EZH2 decreases with consequent reduction of PRC2
complex. H3K27 becomes hypomethylated and the SWI/SNF complex facilitates the DNA binding of tissue specific transcription factors (TF) that
engage histone acetyltransferase (HAT) to allow initiation of transcription.
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found that mi-R29 ectopic expression promotes RMS cell-
cycle arrest, myogenic cell differentiation and tumor
growth inhibition in a xenograft model [25]. Reduction of
miR-29 levels had been previously reported in a small
cohort of alveolar RMS [31]. Altogether, these findings
provide evidence for a key role of EZH2-mediated epige-
netic changes in RMS pathogenesis, which involve also
mutual interactions with microRNAs.
EZH2 in synovial sarcoma
Synovial sarcoma is a malignant cancer that affects pre-
valently young patients and represents almost 10% of all
STSs [32]. It is characterized by the typical translocation
t(X;18)(p11;q11) that generates the fusion between the
synovial sarcoma translocation, chromosome 18 (SS18
or SYT) gene on chromosome 18 and either synovial
sarcoma, X breakpoint 1, 2 or 4 (SSX1, SSX2 or SSX4)
genes on the X chromosome [33]. Previously reported
data showed that chimerical proteins SYT-SSX might
disrupt gene expression mechanisms by functionally
interacting with PcG proteins in synovial cells [34]. In
particular, SYT-SSX2 fusion protein induces down-
stream target-gene deregulation through epigenetic
mechanisms [35]. Recently, EZH2 has been found to
mediate the effects of SYT-SSX activity. Specifically,
SYT-SSX2 represses the expression of the tumor sup-
pressor gene early growth response 1 (EGR1), a regula-
tor of cell cycle, engaging EZH2 on the EGR1 promoter
in synovial sarcoma cells (Figure 2b). EGR1 repression
Figure 2 Possible mechanisms of deregulation of enhancer of zeste homolog 2 (EZH2) in soft tissue sarcoma (STS). (A) In normal
differentiating myoblasts (left panel) promyogenic miR-26a and miR-29 are normally expressed. MiR-26a and miR-29 target EZH2 and yin yang 1
(YY1) mRNAs, respectively, at the 3’ untranslated region (UTR) to induce their degradation. Conversely, in rhabdomyosarcoma (RMS) cells (right
panel) promyogenic miRNAs are downregulated and their loss of function is paralleled by the overexpression of EZH2 and YY1. YY1 recruits
EZH2 to repress the expression of miR-29, establishing a negative regulatory feedback loop. (B) In synovial sarcoma, the chimerical transcription
factor SYT-SSX engages EZH2 that leads to H3K27 trimethylation silencing tumor suppressor genes such as early growth response 1 (EGR1). (C) In
Ewing’s sarcoma the chimerical transcription factor Ewing sarcoma (EWS)/Friend leukemia integration 1 (FLI1) directly contributes to the
maintenance of high level of expression of EZH2.
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tion, and EZH2 and the PRC1 component BMI1 have
been shown to directly bind its promoter, thus support-
ing the existence of a novel epigenetic mechanism of
oncogenesis in synovial sarcoma [36]. This finding illus-
trates how a genetic lesion that generates an oncogenic
trascriptional regulator might exploit EZH2 and other
epigenetic regulators to sustain tumorigenesis.
EZH2 in Ewing’s sarcoma
Ewing’s sarcoma is an embryonal malignancy character-
ized by the t(11;22)(q24;q12) translocation which gener-
ates chimerical Ewing sarcoma (EWS)/ETS fusion
transcription factors. One of the most common fusion
protein found in patients affected by this tumor is EWS/
Friend leukemia integration 1 transcription factor (FLI1)
[37]. EZH2 is expressed at high levels in Ewing’s tumors
[17]. Studying the influence of EZH2 downregulation on
gene expression, Richter and colleagues found that
EZH2 is responsible for the undifferentiated phenotype
of Ewing’s sarcoma by maintaining a stemness gene
expression signature, inhibiting differentiation [17].
Strikingly, EWS/FLI1 has been found to induce the
expression of EZH2 by direct binding to its promoter
in both Ewing’s sarcoma cell lines and human MSCs
(Figure 2c) [17]. EWS/FLI1-dependent activation of
EZH2 seems to be specific, because the other compo-
nents of the PRC2/3 complex are not affected [38].
Notably, human MSCs seem to represent a permissive
environment for the expression of EWS/FLI1, which
induces features in these cells that recapitulate Ewing’s
sarcoma biology. This observation may implicate EZH2
as a coinitiator of Ewing’s sarcoma [39]. Data from
these studies offer an example of how a translocation-
derived fusion product takes advantage of EZH2 recruit-
ing this methyltransferase to drive tumor progression at
the expenses of differentiation.
Concluding remarks and future perspectives
Pediatric STSs, especially those metastatic at diagnosis,
are highly aggressive tumors for which there is still an
unmet medical need of more effective and less toxic
therapeutic approaches. The role of the epigenetic regu-
lator EZH2 in maintaining the embryonal cell phenotype
of STS, its overexpression in these cancers and its func-
tional interaction with many fusion proteins typical of
STS, suggest that EZH2 may represent both a potential
marker of undifferentiated precancerous cells and a rea-
sonable candidate therapeutic target in STS. Increasing
attention is focusing on epigenetic therapies that have
provided promising results in clinical trials for some
human tumors [40-42]. The clinical effectiveness of epi-
genetic therapies in human malignancies has been
recently proved by the observation that, in a randomized
phase III trial, the DNA hypomethylating agent azacyti-
dine prolonged overall survival of myelodysplastic
syndrome (MDS) patients compared to other standard
therapies [43]. The potential efficacy of epigenetic ther-
apy in STS is supported by preclinical studies employing
HDAC inhibitors [36,44-46]. Many studies on cell cul-
ture and animal models indicate that diverse epigenetic
processes synergize to control gene expression. Hence,
different kinds of epigenetic drugs, such as DNA-
demethylating agents and HDAC inhibitors, have been
included in combination treatment protocols [40,47]. It
is noteworthy that, in Ewing’s sarcoma cells, HDAC
inhibitor treatment in vitro induces downregulation of
EZH2 [17], as more recently confirmed in glioma [48],
gallbladder carcinoma [49] and acute myeloid leukemia
[50]. Consistently, in preclinical models of different can-
cers, the antitumor effect of EZH2 inhibition, obtained
through the methyltransferase inhibitor 3’-deazanopla-
nocin (DZNep), is enhanced by addition of HDAC inhi-
bitors [51-53]. DZNep has been shown to act by causing
depletion of PRC2 subunits with subsequent reactivation
of PRC2-silenced genes [54,55]. In addition, it has been
shown that the repressive function of EZH2 on gene
expression is strengthened by the role of DNMTs, with
which EZH2 physically interacts regulating their activity
[56]. In this view, additional usage of DNMTs inhibitors
in protocols targeting EZH2 might improve response in
some tumor contexts. In turn, since HMTs are also
active in non-proliferating cells, the inclusion of EZH2
inhibitors in combination regimens may overcome the
ineffectiveness of DNMTs inhibitors in quiescent cells.
On the other hand, it must be noted that, due to the
complexity of molecular crosstalk involved in epigenetic
control, the use of epigenetic drugs affecting a variety of
molecular networks entails the risk of unforeseeable
effects. For instance, despite their antiproliferative effects
in vitro, treatments employing either HDACs or DNA
methylation inhibitors have been recently reported to
increase in vivo the invasive capabilities of RMS cells
through upregulation of the prometastatic gene Ezrin
[57]. Major questions remain open on the in vivo
mechanism(s) of action of epigenetic drugs. Indeed, the
clinical response to azacytidine in terms of prolongation
of survival in MDS patients does not appear to be
directly correlated with methylation of specific tumor
suppressor genes, though methylation status has been
shown to correlate with poor survival [58]. Even if
future preclinical studies will better clarify the mechan-
isms of action of these drugs on gene expression, precli-
nical findings will need to be validated in humans [59].
Despite these unresolved questions, epigenetic therapy
is a promising approach for targeted anticancer thera-
pies in pediatric STS. Available evidence suggests that
targeting the methyltransferase EZH2 may be potentially
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in pediatric STS. In the future, modulation of EZH2
activity may provide a new line of intervention that
could be combined with epigenetic drugs acting on
other molecular targets and/or conventional cytotoxic
agents to treat these aggressive pediatric tumors.
Acknowledgements
The present work was supported by grants from Ministero della Sanità Italia
(Ricerca Corrente), Associazione Italiana per la Ricerca sul Cancro (AIRC
Project 10338) and Istituto Superiore di Sanità (ISS Project 70BF/8) to RR and
by grants from Ministero della Salute, Italia (Ricerca Corrente) and AIRC
(Special Project 5 × mille) to FL.
Author details
1Department of Oncohematology, IRCCS, Ospedale Pediatrico Bambino Gesù,
Roma, Italy.
2Cancer Institute, University of Mississippi Medical Center,
Jackson, MI, USA.
3Sbarro Institute for Cancer Research and Molecular
Medicine, Temple University, Philadelphia, PA, USA.
4Department of Human
Pathology and Oncology, Università of Siena, Siena, Italy.
5Dipartimento di
Scienze Pediatriche, Università di Pavia, Pavia, Italy.
Authors’ contributions
RC and RR contributed equally to selection and discussion of the literature
and the conception and preparation of the manuscript. FL, AG and LM
contributed to the discussion on clinical implications and reviewed the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 2 February 2011 Accepted: 25 May 2011
Published: 25 May 2011
References
1. Siddiqi S, Mills J, Matushansky I: Epigenetic remodeling of chromatin
architecture: exploring tumor differentiation therapies in mesenchymal
stem cells and sarcomas. Curr Stem Cell Res Ther 2010, 5:63-73.
2. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin
2010, 60:277-300.
3. Vincenzi B, Frezza AM, Santini D, Tonini G: New therapies in soft tissue
sarcoma. Expert Opin Emerg Drugs 2010, 15:237-248.
4. Ganjoo KN: New developments in targeted therapy for soft tissue
sarcoma. Curr Oncol Rep 2010, 12:261-265.
5. Krikelis D, Judson I: Role of chemotherapy in the management of soft
tissue sarcomas. Expert Rev Anticancer Ther 2010, 10:249-260.
6. Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future.
Nat Rev Drug Discov 2006, 5:37-50.
7. Simon JA, Lange CA: Roles of the EZH2 histone methyltransferase in
cancer epigenetics. Mutat Res 2008, 647:21-29.
8. Sparmann A, van Lohuizen M: Polycomb silencers control cell fate,
development and cancer. Nat Rev Cancer 2006, 6:846-856.
9. Ringrose L, Paro R: Epigenetic regulation of cellular memory by the
Polycomb and Trithorax group proteins. Annu Rev Genet 2004, 38:413-443.
10. Rajasekhar VK, Begemann M: Concise review: roles of polycomb group
proteins in development and disease: a stem cell perspective. Stem Cells
2007, 25:2498-2510.
11. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G: Genome
regulation by polycomb and trithorax proteins. Cell 2007, 128:735-745.
12. Laible G, Wolf A, Dorn R, Reuter G, Nislow C, Lebersorger A, Popkin D,
Pillus L, Jenuwein T: Mammalian homologues of the Polycomb-group
gene Enhancer of zeste mediate gene silencing in Drosophila
heterochromatin and at S. cerevisiae telomeres. Embo J 1997,
16:3219-3232.
13. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D,
Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA,
Chinnaiyan AM: EZH2 is a marker of aggressive breast cancer and
promotes neoplastic transformation of breast epithelial cells. Proc Natl
Acad Sci USA 2003, 100:11606-11611.
14. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C,
Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA,
Chinnaiyan AM: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature 2002, 419:624-629.
15. Kuzmichev A, Margueron R, Vaquero A, Preissner TS, Scher M, Kirmizis A,
Ouyang X, Brockdorff N, Abate-Shen C, Farnham P, Reinberg D:
Composition and histone substrates of polycomb repressive group
complexes change during cellular differentiation. Proc Natl Acad Sci USA
2005, 102:1859-1864.
16. Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, Rota R,
Giordano A: Deregulated expression of miR-26a and Ezh2 in
rhabdomyosarcoma. Cell Cycle 2009, 8:172-175.
17. Richter GH, Plehm S, Fasan A, Rössler S, Unland R, Bennani-Baiti IM,
Hotfilder M, Löwel D, von Luettichau I, Mossbrugger I, Quintanilla-
Martinez L, Kovar H, Staege MS, Müller-Tidow C, Burdach S: EZH2 is a
mediator of EWS/FLI1 driven tumor growth and metastasis blocking
endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA
2009, 106:5324-5329.
18. De Giovanni C, Landuzzi L, Nicoletti G, Lollini PL, Nanni P: Molecular
and cellular biology of rhabdomyosarcoma. Future Oncol 2009,
5:1449-1475.
19. Charytonowicz E, Cordon-Cardo C, Matushansky I, Ziman M: Alveolar
rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell?
Cancer Lett 2009, 279:126-136.
20. Merlino G, Helman LJ: Rhabdomyosarcoma–working out the pathways.
Oncogene 1999, 18:5340-5348.
21. Williamson D, Missiaglia E, de Reyniès A, Pierron G, Thuille B, Palenzuela G,
Thway K, Orbach D, Laé M, Fréneaux P, Pritchard-Jones K, Oberlin O,
Shipley J, Delattre O: Fusion gene-negative alveolar rhabdomyosarcoma
is clinically and molecularly indistinguishable from embryonal
rhabdomyosarcoma. J Clin Oncol 2010, 28:2151-2158.
22. Davicioni E, Anderson JR, Buckley JD, Meyer WH, Triche TJ: Gene
expression profiling for survival prediction in pediatric
rhabdomyosarcomas: a report from the children’s oncology group. J Clin
Oncol 2010, 28:1240-1246.
23. Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ,
Anderson MJ: Identification of a PAX-FKHR gene expression signature
that defines molecular classes and determines the prognosis of alveolar
rhabdomyosarcomas. Cancer Res 2006, 66:6936-6946.
24. Lae M, Ahn EH, Mercado GE, Chuai S, Edgar M, Pawel BR, Olshen A, Barr FG,
Ladanyi M: Global gene expression profiling of PAX-FKHR fusion-positive
alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
J Pathol 2007, 212:143-151.
25. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A,
Hall BM, Qualman SJ, Chandler DS, Croce CM, Guttridge DC: NF-kappaB-
YY1-miR-29 regulatory circuitry in skeletal myogenesis and
rhabdomyosarcoma. Cancer Cell 2008, 14:369-381.
26. Ciarapica R, Pezzullo M, Verginelli F, Boldrini R, Sio LD, Stifani S, Giordano A,
Rota R: Abstract #3417: Ezh2 is up-regulated and correlates with Ki67
and CD31 expression in human pediatric rhabdomyosarcoma. AACR
Meeting Abstracts American Association for Cancer Reasearch, Philadelphia,
PA; 2010.
27. Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V: The Polycomb
Ezh2 methyltransferase regulates muscle gene expression and skeletal
muscle differentiation. Genes Dev 2004, 18:2627-2638.
28. Juan AH, Kumar RM, Marx JG, Young RA, Sartorelli V: Mir-214-dependent
regulation of the polycomb protein Ezh2 in skeletal muscle and
embryonic stem cells. Mol Cell 2009, 36:61-74.
29. Wong CF, Tellam RL: MicroRNA-26a targets the histone methyltransferase
Enhancer of Zeste homolog 2 during myogenesis. J Biol Chem 2008,
283:9836-9843.
30. Wang H, Hertlein E, Bakkar N, Sun H, Acharyya S, Wang J, Carathers M,
Davuluri R, Guttridge DC: NF-kappaB regulation of YY1 inhibits skeletal
myogenesis through transcriptional silencing of myofibrillar genes. Mol
Cell Biol 2007, 27:4374-4387.
31. Subramanian S, Lui WO, Lee CH, Espinosa I, Nielsen TO, Heinrich MC,
Corless CL, Fire AZ, van de Rijn M: MicroRNA expression signature of
human sarcomas. Oncogene 2008, 27:2015-2026.
Ciarapica et al. BMC Medicine 2011, 9:63
http://www.biomedcentral.com/1741-7015/9/63
Page 7 of 932. Okcu MF, Despa S, Choroszy M, Berrak SG, Cangir A, Jaffe N, Raney RB:
Synovial sarcoma in children and adolescents: thirty three years of
experience with multimodal therapy. Med Pediatr Oncol 2001, 37:90-96.
33. Jain S, Xu R, Prieto VG, Lee P: Molecular classification of soft tissue
sarcomas and its clinical applications. Int J Clin Exp Pathol 2010, 3:416-428.
34. Soulez M, Saurin AJ, Freemont PS, Knight JC: SSX and the synovial-
sarcoma-specific chimaeric protein SYT-SSX co-localize with the human
Polycomb group complex. Oncogene 1999, 18:2739-2746.
35. de Bruijn DR, Allander SV, van Dijk AH, Willemse MP, Thijssen J, van
Groningen JJ, Meltzer PS, van Kessel AG: The synovial-sarcoma-associated
SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer
Res 2006, 66:9474-9482.
36. Lubieniecka JM, de Bruijn DR, Su L, van Dijk AH, Subramanian S, van de
Rijn M, Poulin N, van Kessel AG, Nielsen TO: Histone deacetylase inhibitors
reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor
early growth response 1 in synovial sarcoma. Cancer Res 2008,
68:4303-4310.
37. Erkizan HV, Uversky VN, Toretsky JA: Oncogenic partnerships: EWS-FLI1
protein interactions initiate key pathways of Ewing’s sarcoma. Clin
Cancer Res 2010, 16:4077-4083.
38. Burdach S, Plehm S, Unland R, Dirksen U, Borkhardt A, Staege MS, Muller-
Tidow C, Richter GH: Epigenetic maintenance of stemness and
malignancy in peripheral neuroectodermal tumors by EZH2. Cell Cycle
2009, 8:1991-1996.
39. Riggi N, Suva ML, Suva D, Cironi L, Provero P, Tercier S, Joseph JM,
Stehle JC, Baumer K, Kindler V, Stamenkovic I: EWS-FLI-1 expression
triggers a Ewing’s sarcoma initiation program in primary human
mesenchymal stem cells. Cancer Res 2008, 68:2176-2185.
40. Candelaria M, Herrera A, Labardini J, González-Fierro A, Trejo-Becerril C, Taja-
Chayeb L, Pérez-Cárdenas E, de la Cruz-Hernández E, Arias-Bofill D, Vidal S,
Cervera E, Dueñas-Gonzalez A: Hydralazine and magnesium valproate as
epigenetic treatment for myelodysplastic syndrome. Preliminary results
of a phase-II trial. Ann Hematol 2010, 90:379-387.
41. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK,
Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC Jr:
Phase 1b-2a study to reverse platinum resistance through use of a
hypomethylating agent, azacitidine, in patients with platinum-resistant
or platinum-refractory epithelial ovarian cancer. Cancer .
42. Vigil CE, Martin-Santos T, Garcia-Manero G: Safety and efficacy of
azacitidine in myelodysplastic syndromes. Drug Des Devel Ther 2010,
4:221-229.
43. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A,
Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM,
Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR,
International Vidaza High-Risk MDS Survival Study Group: Efficacy of
azacitidine compared with that of conventional care regimens in the
treatment of higher-risk myelodysplastic syndromes: a randomised,
open-label, phase III study. Lancet Oncol 2009, 10:223-232.
44. Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, Richon VM,
LaQuaglia MP: Histone deacetylase inhibitors induce growth suppression
and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res
2003, 9:5749-5755.
45. Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, Okada T,
Nakamura T, Matsumoto Y, Iwamoto Y: Antitumor effects of histone
deacetylase inhibitor on Ewing’s family tumors. Int J Cancer 2005,
116:784-792.
46. Hurtubise A, Bernstein ML, Momparler RL: Preclinical evaluation of the
antineoplastic action of 5-aza-2’-deoxycytidine and different histone
deacetylase inhibitors on human Ewing’s sarcoma cells. Cancer Cell Int
2008, 8:16.
47. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, Yang AS,
Aucott T, Dauses T, Odchimar-Reissig R, Licht J, McConnell MJ, Nasrallah C,
Kim MK, Zhang W, Sun Y, Murgo A, Espinoza-Delgado I, Oteiza K, Owoeye I,
Silverman LR, Gore SD, Carraway HE: Early epigenetic changes and DNA
damage do not predict clinical response in an overlapping schedule of
5-azacytidine and entinostat in patients with myeloid malignancies.
Blood 2009, 114:2764-2773.
48. Orzan F, Pellegatta S, Poliani L, Pisati F, Caldera V, Menghi F, Kapetis D,
Marras C, Schiffer D, Finocchiaro G: Enhancer of Zeste 2 (Ezh2) is up-
regulated in malignant gliomas and in glioma stem-like cells.
Neuropathol Appl Neurobiol 2010.
49. Yamaguchi J, Sasaki M, Sato Y, Itatsu K, Harada K, Zen Y, Ikeda H, Nimura Y,
Nagino M, Nakanuma Y: Histone deacetylase inhibitor (SAHA) and
repression of EZH2 synergistically inhibit proliferation of gallbladder
carcinoma. Cancer Sci 2010, 101:355-362.
50. Fiskus W, Buckley K, Rao R, Mandawat A, Yang Y, Joshi R, Wang Y, Balusu R,
Chen J, Koul S, Joshi A, Upadhyay S, Atadja P, Bhalla KN: Panobinostat
treatment depletes EZH2 and DNMT1 levels and enhances decitabine
mediated de-repression of JunB and loss of survival of human acute
leukemia cells. Cancer Biol Ther 2009, 8:939-950.
51. Hayden A, Johnson PW, Packham G, Crabb SJ: S-adenosylhomocysteine
hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-
cancer effects in breast cancer cell lines and synergy with both histone
deacetylase and HER2 inhibition. Breast Cancer Res Treat .
52. Kalushkova A, Fryknäs M, Lemaire M, Fristedt C, Agarwal P, Eriksson M,
Deleu S, Atadja P, Osterborg A, Nilsson K, Vanderkerken K, Oberg F,
Jernberg-Wiklund H: Polycomb target genes are silenced in multiple
myeloma. PLoS One 2010, 5:e11483.
53. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C,
Rao R, Fernandez P, Chen J, Balusu R, Koul S, Atadja P, Marquez VE,
Bhalla KN: Combined epigenetic therapy with the histone
methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone
deacetylase inhibitor panobinostat against human AML cells. Blood 2009,
114:2733-2743.
54. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB,
Liu ET, Yu Q: Pharmacologic disruption of Polycomb-repressive complex
2-mediated gene repression selectively induces apoptosis in cancer
cells. Genes Dev 2007, 21:1050-1063.
55. Wicha MS: Development of ‘synthetic lethal’ strategies to target BRCA1-
deficient breast cancer. Breast Cancer Res 2009, 11:108.
56. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van
Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de
Launoit Y, Fuks F: The Polycomb group protein EZH2 directly controls
DNA methylation. Nature 2006, 439:871-874.
57. Yu Y, Zeng P, Xiong J, Liu Z, Berger SL, Merlino G: Epigenetic drugs can
stimulate metastasis through enhanced expression of the pro-metastatic
Ezrin gene. PLoS One 2010, 5:e12710.
58. Herman JG, Gore S, Mufti G, Fenaux P, Santini V, Silverman L, Seymour J,
Griffiths E, Caraway H, MacBeth K, Mckenzie D, Backstrom J, Beach CL:
Abstract #4746: Relationship among gene methylation, azacitidine
treatment, and survival in patients with higher-risk myelodysplastic
syndromes (MDS): results from the AZA-001 trial. AACR Meeting Abstracts
American Association for Cancer Reasearch, Philadelphia, PA; 2009.
59. Tuma RS: Epigenetic therapies move into new territory, but how exactly
do they work? J Natl Cancer Inst 2009, 101:1300-1301.
60. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B,
Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA,
Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S,
Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and safety of
imatinib mesylate in advanced gastrointestinal stromal tumors. New Eng
J Med 2002, 347:472-480.
61. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS,
Raymond AK, Bramwell VH, Baker LH, Maki RG, et al: Phase III randomized,
intergroup trial assessing imatinib mesylate at two dose levels in
patients with unresectable or metastatic gastrointestinal stromal tumors
expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008,
26:626-632.
62. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH,
Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J,
Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and
safety of sunitinib in patients with advanced gastrointestinal stromal
tumour after failure of imatinib: a randomised controlled trial. Lancet
2006, 368:1329-1338.
63. Mahmood ST, Agresta S, Vigil C, Zhao X, Han G, D’Amato G, Calitri CE,
Dean M, Garrett C, Schell MJ, Antonia S, Chiappori A: Phase II study of
sunitinib malate, a multi-targeted tyrosine kinase inhibitor in patients
with relapsed or refractory soft tissue sarcomas. Focus on 3 prevalent
histologies: Leiomyosarcoma, liposarcoma, and malignant fibrous
histiocytoma. Int J Cancer .
64. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T,
Harmon DC, Bhuchar G, O’Mara MM, D’Adamo DR, Morgan J, Schwartz GK,
Wagner AJ, Butrynski JE, Demetri GD, Keohan ML: Multicenter phase II trial
Ciarapica et al. BMC Medicine 2011, 9:63
http://www.biomedcentral.com/1741-7015/9/63
Page 8 of 9of sunitinib in the treatment of nongastrointestinal stromal tumor
sarcomas. J Clin Oncol 2009, 27:3154-3160.
65. Keohan ML, Morgan JA, D’Adamo DR, Harmon D, Butrynski JE, Wagner AJ,
Schwartz GK, Maki RG, Demetri GD, George S: Continuous daily dosing
(CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas
(STS) other than GIST: Results of a phase II trial. In ASCO Meeting
Abstracts. Volume 26. American Society of Clinical Oncology, Alexandria, VA;
2008:(Suppl):10533.
66. Maki RG, Keohan ML, Undevia SD, Livingston M, Cooney MM, Elias A,
Saulle MF, Wright JJ, D’Adamo DR, Schuetze SM, Sorafenib Sarcoma Study
Group: Updated results of a phase II study of oral multi-kinase inhibitor
sorafenib in sarcomas, CTEP study #7060. In ASCO Meeting Abstracts.
Volume 26. American Society of Clinical Oncology, Alexandria, VA;
2008:(Suppl):10531.
67. Ryan CW, von Mehren M, Rankin CJ, Goldblum JR, Demetri GD,
Bramwell VH, Borden EC: Phase II intergroup study of sorafenib (S) in
advanced soft tissue sarcomas (STS): SWOG 0505. In ASCO Meeting
Abstracts. Volume 26. American Society of Clinical Oncology, Alexandria, VA;
2008:(Suppl):10532.
68. Bertuzzi A, Stroppa EM, Secondino S, Pedrazzoli P, Zucali P, Quagliuolo V,
Comandone A, Basso U, Soto Parra HJ, Santoro A: Efficacy and toxicity of
sorafenib monotherapy in patients with advanced soft tissue sarcoma
failing anthracycline-based chemotherapy. In ASCO Meeting Abstracts.
Volume 28. American Society of Clinical Oncology, Alexandria, VA;
2010:(Suppl):10025.
69. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F,
Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY:
Pazopanib, a multikinase angiogenesis inhibitor, in patients with
relapsed or refractory advanced soft tissue sarcoma: a phase II study
from the European organisation for research and treatment of cancer-
soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol
2009, 27:3126-3132.
70. Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-
Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M,
Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P: A
phase I study of single-agent nilotinib or in combination with imatinib
in patients with imatinib-resistant gastrointestinal stromal tumors. Clin
Cancer Res 2009, 15:5910-5916.
71. Okuno S, Bailey H, Mahoney MR, Adkins D, Maples W, Fitch T, Ettinger D,
Erlichman C, Sarkaria JN: A phase 2 study of temsirolimus (CCI-779) in
patients with soft tissue sarcomas: A study of the mayo phase 2
consortium (P2C). Cancer 2011.
72. Richter S, Pink D, Hohenberger P, Schuette H, Casali PG, Pustowka A,
Reichardt P: Multicenter, triple-arm, single-stage, phase II trial to
determine the efficacy and safety of everolimus (RAD001) in patients
with refractory bone or soft tissue sarcomas including GIST. In ASCO
Meeting Abstracts. Volume 28. American Society of Clinical Oncology,
Alexandria, VA; 2010:(Suppl):10038.
73. Mita MM, Britten CD, Poplin E, Tap WD, Carmona A, Yonemoto L,
Wages DS, Bedrosian CL, Rubin EH, Tolcher AW: Deforolimus trial 106- A
Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-
8669). ASCO Meeting Abstracts 2008, 26(Suppl):3509..
74. Chawla SP, Tolcher AW, Staddon AP, Schuetze S, D’Amato GZ, Blay JY,
Loewy J, Kan R, Demetri GD: Survival results with AP23573, a novel mTOR
inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas:
Update of phase II trial. ASCO Meeting Abstracts 2007, 2:5(Suppl):10076.
75. Anonymous: Ridaforolimus. Drugs R&D 2010, 10:165-178.
76. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM,
Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP,
Gualberto A, Scurr M, de Bono JS, Haluska P: Safety, pharmacokinetics,
and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-
751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1
expansion cohort study. Lancet Oncol 2010, 11:129-135.
77. Patel S, Pappo A, Crowley J, Reinke D, Eid J, Ritland S, Chawla S, Staddon A,
Maki R, Vassal G, Helman L, Sarcoma Alliance for Research and
Collaboration: A SARC global collaborative phase II trial of R1507, a
recombinant human monoclonal antibody to the insulin-like growth
factor-1 receptor (IGF1R) in patients with recurrent or refractory
sarcomas. ASCO Meeting Abstracts 2009, 27(Suppl):10503..
78. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J,
Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H,
Friberg G, Puzanov I: Phase I, pharmacokinetic, and pharmacodynamic
study of AMG 479, a fully human monoclonal antibody to insulin-like
growth factor receptor 1. J Clin Oncol 2009, 27:5800-5807.
79. Scartozzi M, Bianconi M, Maccaroni E, Giampieri R, Berardi R, Cascinu S:
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1
for the treatment of cancer. Curr Opin Mol Ther 2010, 12:361-371.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1741-7015/9/63/prepub
doi:10.1186/1741-7015-9-63
Cite this article as: Ciarapica et al.: Enhancer of zeste homolog 2 (EZH2)
in pediatric soft tissue sarcomas: first implications. BMC Medicine 2011
9:63.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ciarapica et al. BMC Medicine 2011, 9:63
http://www.biomedcentral.com/1741-7015/9/63
Page 9 of 9